NCT01955876View on ClinicalTrials.gov

Fosrenol Post-marketing Surveillance in Japan

CompletedOBSERVATIONAL
Enrollment

343

Participants

Timeline

Start Date

October 10, 2013

Primary Completion Date

February 18, 2016

Study Completion Date

August 5, 2016

Conditions
HyperphosphatemiaKidney Disease
Interventions
DRUG

Lanthanum Carbonate (Fosrenol, BAY77-1931)

Patients treated with Fosrenol in daily clinical practice.

Trial Locations (1)

Unknown

Multiple Locations

Sponsors

Lead Sponsor

Bayer
All Listed Sponsors
lead

Bayer

INDUSTRY

NCT01955876 - Fosrenol Post-marketing Surveillance in Japan | Biotech Hunter | Biotech Hunter